Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Investor Presentation (June 2022)
35 slides from Jubilant Pharmova's investor presentation, June 2022
Slide 1: Investor Presentation June 2022
Investor Presentation June 2022
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Jubilant Pharmova Limited – Overview
Jubilant Pharmova Limited – Overview Jubilant Pharmova Limited FY22 Revenue Split Segment Wise Region Wise 100% CRDS China and ROW India 7% 5% Jubilant Pharma Limited 7% Europe & Japan Specialty 7% 100% Generics Pharmaceuticals 19.0% 43% Jubilant Biosys Limited 100% Jubilant Therapeutics India Limit
Slide 4: Jubilant Pharmova – Business Snapshot
Jubilant Pharmova – Business Snapshot Pharmaceuticals Contract Research and Development Services Specialty Pharmaceuticals Fully integrated Drug Discovery services provider 1 #3 radiopharmaceutical manufacturer in the US Facilities in Noida and Bangalore Radio Manufacturing facility based in
Slide 5: High-Quality, World-Class, Low Cost Manufacturing Footprint and Operational Facilities
High-Quality, World-Class, Low Cost Manufacturing Footprint and Operational Facilities Biosys Gr. Noida Facility Spokane, Washington, USA Contract manufacturing of Sterile injectable and Allergy therapy Roorkee, Uttarakhand Generics manufacturing Noida Montreal, Canada Corporate Office Contrac
Slide 6: Experienced Management Team with High Standards of Corporate Governance
Experienced Management Team with High Standards of Corporate Governance Shyam S Bhartia Hari S Bhartia Chairman Co-Chairman & Managing Director 43 industry years in pharmaceutical, specialty 37 industry years in pharmaceutical, specialty chemicals, foods, oil and gas, aerospace and IT chemicals, foo
Slide 7: Pharmaceuticals Business - Jubilant Pharma
Pharmaceuticals Business - Jubilant Pharma
Slide 8: Pharmaceuticals Business Structure and Evolution: Strong M&A track record
Pharmaceuticals Business Structure and Evolution: Strong M&A track record FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY21 JLL acquired API Acquired Created R&D Acquired a majority Acquired Acquired Draxis Commissioned Acquired Consolidation of Completed JPL enter
Slide 9: Each of the businesses operate in growing markets with considerable headroom for growth
Each of the 6 businesses operate in growing markets with considerable headroom for growth Market Growth Segments Business Units Market Dynamics Size, $Bn Outlook High barriers to entry (complex manufacturing, customer Specialty Radio- stickiness, and stringent regulations) and limited price 6-8% Pha
Slide 10: Each of the six businesses are at different stages of evolution
Each of the six businesses are at different stages of evolution Stages of Evolution Sustain Momentum Scale-up Turnaround Maintain growth rates and protect Leverage robust platforms and market Restructure for profitability margins to generate cash tailwinds to drive profitable growth Radiopharmaceuti
Slide 11: Looking ahead, markers are in place for sustained/accelerated growth across portfolio
Looking ahead, markers are in place for sustained/accelerated growth across portfolio Stages of Evolution Sustain Momentum Scale-up Turnaround Maintain growth rates and protect Leverage robust platforms and market Restructure for profitability margins to generate cash tailwinds to drive profitable g
Slide 12: Sustained out-performance to be driven by five key differentiators
Sustained out-performance to be driven by five key differentiators • Businesses with different market dynamics and stage of evolution 1 • US-centric front-end and manufacturing help drive innovation and is supported by robust operations from India 1 2 • Specialty businesses have leadership in the US
Slide 13: Business Overview
— = _ Busine s Overvi |
Slide 14: Radiopharmaceuticals – Business Overview
Radiopharmaceuticals – Business Overview Uncompromised Quality Innovation Leadership • Founded in 1955, acquired by Jubilant Pharma in 2008 • The essence of Jubilant Radiopharma is a • #3 radiopharmaceutical manufacturer in commitment to the highest quality. Our the US based on revenue • Headquarter
Slide 15: Radiopharmacies – Business Overview
Radiopharmacies – Business Overview # 2 commercial radiopharmacy network in the US Facilities also include three operational cyclotrons Multi-year agreements with GPOs in place 48 SPECT radiopharmacies spread across 22 states Access to 13 PET radiopharmacies via SOFIE 800+ employees c.2.8 mn+
Slide 16: Allergy Immunotherapy (AIT) – Business Overview
Allergy Immunotherapy (AIT) – Business Overview Products Product range includes portfolio of 100+ different allergenic extracts, six insect venom products and exclusive skin diagnostic testing devices #2 player in the allergenic SCIT extract market in the US and the sole supplier for venom immun
Slide 17: CMO – Business Overview
CMO – Business Overview Overview CMO Services across product segments Sterile injectables accounts for 80% CMO revenue while non-sterile products account for the Full suite of services to our customers including supply chain support, balance 20% CMO revenue lab testing services, regulatory submiss
Slide 18: API – Business Overview
API – Business Overview Highlights • Over 50% API sales are to regulated markets, resulting in high customer retention levels • 75–80% sales to third-party customers and balance to internal generics business • ~80% of the commercialized portfolio is in lifestyle-disease-related therapeutic areas suc
Slide 19: Generics – Business Overview
Generics – Business Overview Overview Market leader in the US in select products(1) Capabilities in multiple dosage forms Vertical integration via our APIs business Supported by in-house R&D facilities for formulation development Broad therapeutic areas covered include Cardiovascular Syste
Slide 20: Contract Research & Development Services - Business Overview
Contract Research & Development Services - Business Overview Overview Discovery Services up to IND & GMP Provides new Drug Discovery services to global innovators in US, EU, Full suite of services to our customers including supply chain support, lab testing services and project management Japan & A
Slide 21: Jubilant Therapeutics: Developing best-in-class precision therapies in oncology and autoimmune diseases
Jubilant Therapeutics: Developing best-in-class precision therapies to address significant unmet medical needs in oncology and autoimmune diseases 21
Slide 22: Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases
Jubilant Therapeutics: Differentiated portfolio in oncology & autoimmune diseases 22
Slide 23: Jubilant Pharmova - Financials
Jubilant Pharmova - Financials
Slide 24: Financial Performance | P&L
Financial Performance | P&L Revenue from Operations Revenue by Segment 5% 7% 6% 9% 5,790 6,130 24% 19% 20% 14% (Rs Crore) 31% 36% 31% 33% 1,580 1,528 38% 43% 38% 45% FY21 FY21 Q4 FY21 Q4 FY22 FY21 FY22 Q4 FY21 Q4 FY22 Specialty Pharma CDMO Generics CRDS EBITDA PAT Margin 23.2% 19.0% 24.1% 16.0% 9.4%
Slide 25: Financial Performance | Balance Sheet
Financial Performance | Balance Sheet Return On Capital Employed (ROCE) Leverage Net Debt/ EBITDA 1.36x 1.67x 14.8% (% age) 2,938 (Rs Crore) 10.5% 2,600 1,928 1,954 FY21 FY22 FY21 FY22 Gross Debt Net Debt Capital Expenditures Working Capital 4.5% 7.1% 86 96 437 1,615 (Rs Crore) (Rs Crore) 276 1,429
Slide 26: API Demerger Announcement
API Demerger Announcement
Slide 27: Update on API Demerger
Update on API Demerger • In July 2021, the Board of Directors of Jubilant Pharmova Limited (JPM) approved demerger of the Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Limited(JGL) and vesting of the same with JPM, on a going concern basis, to be implemented through a sche
Slide 28: The re-organisation will ensure presence across the value chain
The re-organisation will ensure presence across the value chain Patent Life On -patent Off Patent Type of Discovery Development Commercialization Service Research Discovery Preclinical Clinical Registration Manufacturing Drug Drug discovery DMPK Phase I trials Approval Pharmacological Permission to
Slide 29: Annexure
Annexure 29
Slide 30: Financial Performance | Q4'FY22
Financial Performance | Q4’FY22 Revenue was at Rs 1,528 Crore versus Rs 1,580 Crore in Q4'FY21 • Pharmaceuticals revenue at Rs 1,380 Crore as compared to Rs 1,486 Crore in Q4'FY21 • Contract Research and Development Services witnessed strong growth with revenue at Rs 142 Crore as against Rs 94 Cro
Slide 31: Financial Performance | FY22
Financial Performance | FY22 Particulars1,2 FY21 FY22 YoY (%) Revenue Revenue was Rs 6,130 Crore versus Rs 6,099 Crore in FY21 Pharmaceuticals 5,790 5,651 -2% • Pharmaceuticals revenue at Rs 5,651 Crore as compared to Rs Contract Research and Development Services 305 457 50% 5,790 Crore in FY21 Pr
Slide 32: Appendix
Appendix 32
Slide 33: Income Statement – Q4 & FY22
Income Statement – Q4 & FY22 Particulars1,2 Q4'FY21 Q3'FY22 Q4'FY22 YoY (%) FY21 FY22 YoY (%) Total Revenue from Continuing Operations Pharmaceuticals 1,486 1,186 1,380 (7%) 5,790 5,651 (2%) Contract Research and Development Services 94 120 142 51% 305 457 50% Proprietary Novel Drugs 0 0 0 - 4 2 (50
Slide 34: For more information
For more information For Investors: For Investors: Siddharth Rangnekar VineetVineet V MayerV Mayer CDR India Ph: +91Ph: +91 120 436120 436 1103 1103 Ph: +91 +91 9769919966 E-mail:E-mail: vineet.mayer@jubl.com vineet.mayer@jubl.com E-mail: siddharth@cdr-india.com For Media: Clayton Dsouza Sudhakar Sa
Slide 35: Thank You
Thank You Corporate Office 1-A, Sector-16A, Noida-201301, UP, India Email: support@jubl.com 35
Jubilant Pharmova — Investor Presentation (June 2022) on 6ix